Skip to main content
Black Health logo Black Health

Clinical interactions & pharmacogenomics

Drug interaction checker

Enter up to four medications. The tool checks every pair against a curated library sourced from FDA labels and CPIC Guidelines, and flags pharmacogenomic differences that matter for Black patients (CYP2C19, CYP2D6, VKORC1, ADRB2).

Your medications

Start typing for suggestions.

Start typing for suggestions.

Start typing for suggestions.

Start typing for suggestions.

Reset

Data sources: FDA labels, CPIC Guidelines, ACC/AHA & ADA guidelines.

Pharmacogenomics for Black patients (1)

  • Metoprolol

    CYP2D6

    Metoprolol is CYP2D6-metabolized. Poor metabolizers accumulate drug and develop bradycardia at typical doses. Strong CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion) create a functional poor-metabolizer state regardless of genotype.

    What this means for Black patients: Consider atenolol (renally cleared, no CYP2D6 involvement) when switching antidepressants to or from CYP2D6 inhibitors.

    Source: CPIC 2023 draft Guideline for Beta Blockers.

Always talk to your pharmacist. This tool is educational and only surfaces interactions we can cite. Pharmacy software checks every combination in your full medication regimen against continually-updated databases like Lexicomp and Micromedex, use this tool to sharpen the questions you bring to that conversation, not to replace it.

Related resources